Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance.

"Our execution across our business continues to chart a clear path to delivering on Vision 2025. We have further strengthened our operations, and our business is performing well as we've diversified our revenue streams and rapidly deleveraged while delivering meaningful top-and bottom-line growth," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals in a press release.

"We're pleased with the performance across our key products (…) Epidiolex® delivered significant year-over-year growth driven by underlying demand (…) Based on this performance, we are raising the mid-point for our 2022 full-year revenue guidance and continue to focus on long-term sustainable growth," Cozadd continued.

Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals explained further.

"We have prioritized and …

Full story available on Benzinga.com